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a b s t r a c t
Background: Posttreatment surveillance for the local and regional recurrence of the head and
neck squamous cell carcinoma often requires a multimodality techniques that include PET
combined with CT, MRI, US.
Aim: The purpose of this study is to compare the diagnostic performance of two imag-
ing techniques (PET/CT and US), and their combined use for the detection of a subclinical
regional recurrence in patients after HNSCC treatment.
Materials and methods: 83 patients after completion of the HNSCC treatment underwent both
US and PET/CT on the mean follow-up of 14 months after initial treatment.
Results: The sensitivity and speciﬁcity of PET/CT were 86% and 82%, respectively; US values
reached 81% and 87%, respectively. PPVwas 79% for PET/CT, and 83% for US. NPVwas 89% for
PET/CT, and 85% for US. The overall accuracy for PET/CT and US was 84% for both methods.Conclusion:US could be regarded as complementary to PET/CTas the procedureswithhighest
sensitivity, speciﬁcity and NPV for detecting subclinical regional recurrences after HNSCC
treatment.
land© 2011 Greater Po1. Background
Head and neck squamous cell carcinoma is the sixth most
commonmalignancy in Europe1 and refers to a groupofmalig-
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z.o.o. All rights reserved.
nancies involving the upper aerodigestive tract, including the
oral cavity, oropharynx, nasopharynx, hypopharynx, and lar-
ynx. Treatment often requires a multimodality approach that
includes combinations of surgery, radiation, and chemother-
apy. Such treatment frequently causes signiﬁcant distortions
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Primary tumor site, stage and nodal status in
patients treated in ENT Department in Poznan due to
HNSCC.
Age (years)
Mean range 57
Sex
Male 64
Female 19
Total 83
Tumor site
Oral cavity 36
Oropharynx 3
Hypopharynx 6
Larynx 20
Salivary gland 7
Nasal cavity and paranasal sinuses 11
Tumor stage
T1 7
T2 26
T3 14
T4 36
Nodal status
N0 39
N1 12
N2 21
N3 11reports of practical oncology and
f normal tissues, such as edema or ﬁbrosis, which may
bscure an early detection of recurrent disease and postpone
subsequent salvage treatment.Positron emission tomogra-
hy (PET)withﬂuorine 18-ﬂuorodeoxyglucose (FDG) combined
ith computed tomography (CT) enable highly precise local-
zation of the metabolic abnormalities, which cannot be
chieved with conventional morphologic imaging such as
omputed tomography (CT) and magnetic resonance (MRI).2–4
Ultrasonography (US) has been widely used for the assess-
ent of the cervical lymph node status both in staging and
osttreatment evaluation.5
To the best of our knowledge, many studies have investi-
ated the accuracy of above mentioned modalities for staging
f the tumor, but the actual usefulness of combined use of
ET/CT and US has not yet been determined in the posttreat-
ent surveillance for the regional recurrence of the head and
eck squamous cell carcinoma (HNSCC).
. Aim
ased on the fact that the incidence of distant metastases,
urvival, and tumor control are dependent on the status of
ervical lymph nodes,6 the purpose of this retrospective study
as to compare the diagnostic performance of two imaging
echniques (PET/CT and US), and their combined use for the
etection of a subclinical regional recurrence in patients after
NSCC treatment.
. Material and methods
.1. Patients
etween December 2007 and April 2010, 83 patients, who had
ompleted their HNSCC treatment, underwent US in the ENT-
epartment in Poznan and PET/CT in the PET/CT Center in
oznan and Warsaw. All patients completed these two exam-
nations (PET/CT and US) at the mean follow-up of 14months
minimum 5, maximum 22months) after initial treatment.
dditionally, clinical otolaryngological examination did not
eveal any suggestion of recurrence in any of the patients
nder study.
The diagnosis of SCC was proved pathologically in all
atients. Table 1 shows primary tumor sites, i.e. the larynx
n=20), pharynx (n=9), tonsil (n=6), tongue (n=10), oral cavity
n=17), skin (n=3), maxillary region (n=10), and others (n=8).
ll patients underwent a complete resection of the primary
umor or a debulking procedure, depending on the initial size
f the tumor. Size of the tumor (T) is also presented in Table 1
7 patients had T1, 26 – T2, 14 – T3, 36 – T4). All patients were
lso treatedwith theneck dissections,whichwere determined
ased on the clinical and imaging ﬁndings estimating the size
nd number of the lymph nodes (N).
.2. Imaging techniques.2.1. PET/CT
ll the data were acquired with a combined PET/CT system
Discovery ST, GE Health Systems, Milwaukee, WI), permit-ting the acquisition of co-registered CT and PET images in one
session.
Patients fasted for at least 4h preceding the scanning,
which started 60min after the injection of 18F-FDG. All
patients were tested for a normal glucose level [range
80–120mg/dl (4.4–6.7mmol/l)] before scanning. Patients with
elevated glucose levels were rescheduled and scanned with
normal glucose levels. Oral CT contrast agent (Gastrograﬁn,
Schering, Germany) was given before the injection of 18F-FDG.
Patients were examined in the supine position. No intra-
venous contrast agent was given. Initially, the CT scan was
acquired starting from the level of the head using the fol-
lowing parameters: 40mAs, 140kV, 0.5 s/tube rotation, slice
thickness 4.25mm. Immediately following the CT acquisition,
a PET emission scan was acquired with an acquisition time
of 2.5min per cradle position with a one-slice overlap in 3D
mode. The eight cradle positions starting from the head to the
knees resulted in an acquisition time of approximately 20min.
The CT data were used for attenuation correction of the PET
datasets and the images were reconstructed using a standard
iterative algorithm (OSEM). The acquired images were viewed
with software providing multiplanar reformatted images of
PET alone, CT alone and fused PET/CT using the Advantage
Workstation (GE Health Systems, Milwaukee, WI).
3.3. US
US examinations were performed using an Aloka SSD1700
ultrasonographer (Japan, Tokyo Diagnostic Ultrasound Sys-
tem) with a 7.5-MHz liner transducer probe. Color Doppler US
was performed with low ﬂow settings for optimal detection of
signals from lymph node vessels.
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Table 2 – PET/CT and US results for detecting regional recurrence of HNSCC.
Primary tumor site PET/CT for regional recurrence USG for regional recurrence
TP FP TN FN TP FP TN FN
Oral cavity 15 3 15 3 15 1 16 4
Oropharynx – 1 2 – – 1 2 –
Hypopharynx 1 2 3 3 1 1 1
Larynx 7 – 11 2 4 1 14 1
Salivary glands 4 – 3 – 4 2 1 –
Nasal cavity and paranasal sinuses 4 2 5 – 3 – 7 1
29 6 41 7
ive.
Table 3 – Sensitivity, speciﬁcity, PPV, NPV, and accuracy
of both PET/CT and US for regional HNSCC recurrence.
PET/CT USG
Sensitivity 86% 81%
Speciﬁcity 82% 87%
PPV 79% 83%
NPV 89% 85%
Accuracy 84% 84%Total 31 8 39 5
TP: true positive; FP: false positive; TN: true negative; FN: false negat
3.4. Image interpretation
ThePET/CT imageswere reviewedandanalyzedby twoexperi-
enced physicians: nuclearmedicine physician and radiologist.
For all of the patients, the attenuation-corrected PET images
were reviewed as maximum intensity projections and in
transaxial, coronal, and sagittal planes. The PET images and
the corresponding CT images of the PET/CT study were ana-
lyzed for the presence of focal lesions with elevated 18F-FDG
uptake. Lesions were interpreted as metabolically positive if
the 18F-FDG standardized uptake value was greater than 3.0.
If a focal FDG-active lesion was detected, the exact anatomi-
cal localization was determined on the fused PET/CT images.
The interpretation of active lesions was based on the location
and morphology. Areas of physiological activity (e.g. mus-
cles, brown adipose tissue, palatine tonsils, salivary glands)
were excluded unless uptakewas asymmetrical (right–left dif-
ference of SUV≥1.0).Cervical lymph nodes visualized by US
were considered to be metastatic, thus warranting suspicion
of regional recurrence, if they showed the following criteria:
a short axis diameter >7mm, the long-to-short axis ratio < 2,
absence of an echogenic hilum, and the absence of normal
hilar blood ﬂow and/or the presence of abnormal peripheral
blood ﬂow on color Doppler.7–9
4. Results
The study group consisted of 83 patients, 19 women and 64
men, with a mean age of 57. Patient pretreatment pathologic
status is summarized in Table 1.
According to PET/CT, 36 patients had regional extension of
malignant process. The results for the neckwere true negative
in 39 patients, true positive in 31, false positive in 8, and false
negative in 5. US ﬁndings were true negative in 41 patients,
true positive in 29, false positive in 6, and false negative in 7
(Table 2). Both PET/CT and US results were conﬁrmed whether
by open, explorative biopsy or ﬁne needle aspiration. For 10
patients, salvage surgery was performed, 26 patients under-
went chemotherapy, radiotherapy or palliative treatment.
As presented in Table 3, the sensitivity and speciﬁcity of
imaging modalities in this study for the early diagnosis of
HNSCC recurrence were 86% and 82%, respectively for PET/CT.
For US, the values reached 81% and 87%, respectively. The pos-
itive predictive value (PPV)was 79% for PET/CT, and 83% forUS.
The negative predictive value (NPV) was 89% for PET/CT, andPPV: positive predictive value; NPV: negative predictive value.
85% for US. The overall accuracy for PET/CT and US was 84%
for both methods.
5. Discussion
The highest incidence of HNSCC recurrence occur within
2years after initial treatment.10 A delay in the detection of
recurrent HNSCC has been shown to have negative clinical
outcome after treatment. Patients with recurrent, early-stage
HNSCC who undergo salvage surgery have a 70% rate of
2-year relapse-free survival, whereas those with recurrent,
advanced-stage HNSCC undergoing surgical salvage have just
a 22% rate of 2-year relapse-free survival.11 Early diagno-
sis and accurate identiﬁcation of recurrent HNSCC are thus
essential for successful treatment. Clinical examination and
imaging are recommended at 1–3-month intervals (1–2-month
intervals for tumors with aggressive histology) for the ﬁrst
year, at 2–4-months intervals during the second year, every
4–6months during the next 3 years, and every 6–12months
thereafter.12 New mass, pain, vascular compromise, and
neurologic deﬁcit are indications for immediate clinical exam-
ination and imaging.
According to the literature, patients with any advanced-
stage tumor and low clinical suspicion for recurrence or with
any stage of disease and moderate clinical suspicion of recur-
rent tumor should undergo PET/CT as an initial investigation,
followed by CT, MRI, and US.2 One could argue which of these
modalities, used in clinical practice, is the best to detect occult
metastases, not detectable on routine physical examination.
In the current study, we evaluated the diagnostic per-
formance of PET/CT and US in patients with no sign of
regional recurrence at the mean follow-up of 10months. To
determine the abnormality on US we relied on lymph node
size and shape criteria whereas PET/CT provided additional
radio
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nformation about metabolism and precise localization of the
ccult recurrence.
Our results show that ultrasound has high diagnostic per-
ormance (sensitivity 81%, speciﬁcity 87%, accuracy 84%, PPV
3%, NPV 85%) for the detection of cervical lymphnodemetas-
ases, i.e. regional recurrence. The ﬁndings of our study agree
ith daily practice and literature where US is the most com-
only used modality with a high accuracy to detect cervical
ymph node metastases.13 Compared to PET/CT, US has been
hown to be as sensitive, speciﬁc and accurate, if not superior,
n detecting neck node metastases.
The main disadvantages of US compared to PET/CT are the
oderate inter-observer variation and imaging limited to soft
issue. On the other hand, US offers numerous advantages
ver PET/CT. It is less time consuming, inexpensive, repeat-
ble, well tolerated by patients, and does not expose a patient
o radiation.
Evaluating the diagnostic performance of PET/CT, this
maging modality was found to be both highly sensitive (86%)
or detection of HNSCC recurrences and to have high NPV
89%), but it demonstrated low speciﬁcity (82%) and PPV
79%). Our ﬁndings support the literature in conﬁrming that
ET/CT alone cannot reliably predict the presence of resid-
al cervical metastatic disease, but its negative predictive
alue (NPV) is high enough to rule recurrence out.14–18 It indi-
ates that a positive result is not particularly useful to the
linician but a negative one can reliably allow the patient
o avoid neck dissection and further imaging.Fused PET/CT
ffers numerous advantage over other imaging modalities.
t is typically applied as a whole-body imaging technique
n contrast to regional application of US. It is a relatively
tandardized technique visualizing both soft and bone struc-
ures that can be performed at most referral hospitals.
urthermore, the CT aspects allow for assessment and visu-
lization of PET-negative lesions. General disadvantages of
ET/CT include its costs, radiation exposure, use of intra-
enous contrast, interpretation challenges. The latter include
alse-positive results that may occur because of infections; a
hysiologically increased uptake in structures such as pala-
ine tonsils, salivary glands, and masticators, oral cavity,
eck, and laryngealmuscles; uptake in reactive nonneoplastic
ymph nodes; and, if within 4–6months after surgery, non-
nfectious inﬂammation and granulation at the surgical site
ﬂare phenomenon); false-negative results, on the other hand,
an occur if malignancy is present in structures with phys-
ologically elevated metabolism (e.g., tonsillar carcinoma); if
umor size is below the resolution of current PET/CT scan-
ers (typically 8mm); if the tumor is not FDG-avid; or if
patient is scanned too early after completion of primary
reatment.19–21
Whether US or PET/CT imaging alone is accurate enough
o guide treatment decisions in patients with head and
eck malignancies, depends on the ability of these imag-
ng techniques to rule out the presence of occult recurrence.
n the basis of this study, we believe that both PET/CT
nd US with its high NPV are a valuable part of the diag-
ostic process in patients with no evidence of suspicious
ymphadenopathy ormass on the physical examination. How-
ver, we can never refrain from biopsy in further treatment
lanning.therapy 1 6 ( 2 0 1 1 ) 184–188 187
6. Conclusion
Thishistology-controlled study shows that at presentUS could
be regarded as complementary to PET/CT as a procedure with
the highest sensitivity, speciﬁcity and NPV for detecting sub-
clinical regional recurrences after HNSCC treatment. These
have become routine methods in our institution.
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